Epigenetics Discovery Congress

Size: px

Start display at page:

Download "Epigenetics Discovery Congress"

Wilfrid Moody
5 years ago
Views:

2nd Annual MNM CONFERENCES Epigenetics Discovery Congress 8 th - 9 th September 2016, London, UK Epigenetics has fl ourished to become one of the most revolutionary areas of science over the past

While the promise of epigenetics is signifi cant, it also presents some interesting challenges like pathways and mechanisms underlying epigenetics, using right screening platforms, bottlenecks in

At the 2 nd Annual Epigenetics Discovery Congress, which will be held on 8-9 September 2016 in London, UK aims to provide a platform for researchers, academics and industry professionals working in

1 2nd Annual MNM CONFERENCES Epigenetics Discovery Congress 8 th - 9 th September 2016, London, UK Epigenetics has fl ourished to become one of the most revolutionary areas of science over the past decade. Also, advances in the understanding of epigenetic processes, have led to a burst in interest in this area as a potential source of new targets for the discovery of medicines. While the promise of epigenetics is signifi cant, it also presents some interesting challenges like pathways and mechanisms underlying epigenetics, using right screening platforms, bottlenecks in translational and clinical phase, collating epigenetics data with proper analysis and fi nding the right biomarkers. At the 2 nd Annual Epigenetics Discovery Congress, which will be held on 8-9 September 2016 in London, UK aims to provide a platform for researchers, academics and industry professionals working in epigenetic research to avail an opportunity & explore the potential of epigenetics to contribute towards novel and existing therapeutics, current progress and trends in the inclusion of epigenetics in drug discovery and development. Along with the advancements in technologies and solutions, the conference will also focus on highlighting some of the emerging trends in terms of drug discovery with respect to evolving targets, inhibitors, biomarkers and clinical success of epigenetics across various diseases. Why Attend? Review the importance of the strongly growing epigenetic market Discuss the latest epigenetic breakthroughs in your fi eld of epigenetic studies Explore new avenues to network and showcase your epigenetic research work and discoveries Discuss the use of Biomarkers as a tool for achieving optimal detection Network with your academic and industry colleagues to brainstorm on latest epigenetic application Review the latest epigenetic tools and technologies available in the market to aid your research Sponsor/Exhibitor: 1

Advisory Panel: Dr. Tamara Maes Chief Scientifi c Offi cer, Oryzon, Spain Dr. Paola B. Arimondo Research Director, CNRS EtaC, France Dr.

Richard Chesworth Senior Vice President Molecular Discovery Epizyme, USA Dr. Paola B. Arimondo Research Director CNRS EtaC, France Prof. A. Ganesan Professor of Chemical Biology University of East Anglia, Norwich, UK Prof.

Moshe Szyf Glaxo Smith Kline and James McGill Professor, Department of Pharmacology and Therapeutics, McGill University Medical School, Canada Prof. Dr.

Richard Meehan Programme Leader, Chromosomes and Gene Expression MRC Human Genetics Unit MRC IGMM, University of Edinburgh, UK Dr. Tamara Maes Chief Scientifi c Offi cer Oryzon, Spain Dr.

Irene Maeve Rea Emeritus Professor, School of Medicine, Dentistry and Biomedical Science,Ulster University, Ireland Dr.

2 Advisory Panel: Dr. Tamara Maes Chief Scientifi c Offi cer, Oryzon, Spain Dr. Paola B. Arimondo Research Director, CNRS EtaC, France Dr. Hajji Nabil Lecturer in epigenetics and translational oncology, Imperial College London, UK Speakers: Dr. Daniel Vitt CSO 4SC AG, Germany Dr. Richard Chesworth Senior Vice President Molecular Discovery Epizyme, USA Dr. Paola B. Arimondo Research Director CNRS EtaC, France Prof. A. Ganesan Professor of Chemical Biology University of East Anglia, Norwich, UK Prof. Dr. Manon van Engeland Dept. of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Netherlands Dr. Moshe Szyf Glaxo Smith Kline and James McGill Professor, Department of Pharmacology and Therapeutics, McGill University Medical School, Canada Prof. Dr. Reinhard Stöger Associate Professor in Epigenetics University of Nottingham, England Prof. Rosalind M John Division Leader for Pathophysiology and Repair Cardiff School of Biosciences, UK Prof. Richard Meehan Programme Leader, Chromosomes and Gene Expression MRC Human Genetics Unit MRC IGMM, University of Edinburgh, UK Dr. Tamara Maes Chief Scientifi c Offi cer Oryzon, Spain Dr. Stephen J Shuttleworth Chief Scientifi c Offi cer Karus Therapeutics Ltd, England Prof. Dr. F.J. (Frank) Dekker Associate professor, Medicinal Chemistry, University of Groningen, Netherlands Prof. Irene Maeve Rea Emeritus Professor, School of Medicine, Dentistry and Biomedical Science,Ulster University, Ireland Dr. Gian Gaetano Tartaglia Group Leader, Gene Function & Evolution, Centre for Genomic Regulation (CRG), Barcelona, Spain Dr. Tobias A. Knoch Group Leader Biophysical Genomics, Cell Biology & Genetics Erasmus MC, Rotterdam, The Netherlands Prof. Guro Elisabeth Lind Group leader Epigenetics, Department of Molecular Oncology, Institute for cancer research, Oslo University Hospital, Norway Dr. Brian Lohse Associate Professor, EpiDiscoverY, Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, University of Copenhagen, Denmark Dr. Hajji Nabil Lecturer in epigenetics and translational oncology Imperial College London, UK Dr. Manfred Koegl Director Oncology Research Boehringer Ingelheim, Vienna, Austria Prof. Dr. Gianluca Sbardella Associate Professor of Medicinal Chemistry, Head of EpigeneticMedChemLab Università di Salerno, Italy 2

3 Conference Day One, Thursday, 8 th September :00 Registration and Refreshments 08:50 MnM Conferences Welcome Address 08:55 Opening remarks by the Chair Developmental Biology and Environment 09:00 Structural and regulatory factors of chromatin for developing novel therapeutic approaches for human diseases Chromatin Biology and Mechanism Chromatin marks: Histone modifi cations, DNA modifi cations and novel discoveries Role of chromatin in human diseases Prof. Dr. Gianluca Sbardella, Associate Professor of Medicinal Chemistry, Head of EpigeneticMedChemLab, Università di Salerno, Italy 09:25 Epigenetic profiling and environmental challenge 5mC/5hmC profi ling tracks environmental exposure in model systems Allows identifi cation of potential epigenetic predictors of end point pathologies Studying the effects of environmental triggers on the epigenome will enable identifi cation of novel biomarkers Prof. Richard Meehan, Programme Leader, Chromosomes and Gene Expression, MRC Human Genetics Unit MRC IGMM, University of Edinburgh, UK 09:50 Stability and flux of DNA methylation patterns Genomic programs regulating energy balance evolved to be buffered or canalised against genetic variation Large genetic regulatory networks can acquire novel epigenetic states in response to environmental challenges A new metric to quantify and compare epigenetic fl exibility and stability across loci, cell types, and developmental stages Prof. Dr. Reinhard Stöger, Associate Professor in Epigenetics, University of Nottingham, England 10:15 Presentation by NuGEN 10:45 Morning Refreshments Networking Poster presentation One to One meetings 11:30 Environmental programming of maternal care and offspring behaviour by an epigenetic mechanism Prenatal environment and the developing placental epigenome Placental function and fetal growth Dual programming of maternal care and offspring behaviour Prof. Rosalind M John, Division Leader for Pathophysiology and Repair, Cardiff School of Biosciences, UK Translational Epigenetics 11:55 Overcoming bottlenecks in the translational phase This session will focus on overcoming bottlenecks in the translational phase Speaker TBA 12:20 Epigenetic regulation of the tumour micro environment (TME) - immuno oncology meets epigenetics 4SC-202 is a new clinical stage epigenetic regulator of the TME Enhanced T-cell infiltration in tumours may offer a unique clinical boost of responses to checkpoint inhibitors Further approaches of epigenetic immune regulation - beyond HDAC inhibitors Dr. Daniel Vitt, Vorstand, CSO, 4SC AG, Germany 12:45 Epigenetic regulation of epithelial homeostasis: an emerging story of health and disease Urothelium is a transitional epithelium that functions as a self-repairing, urinary barrier within the bladder and associated urinary tract. I will present experimental evidence that at the cellular level, the homeostasis of human urothelium is regulated epigenetically I will further consider how local and environmental factors effecting epigenetic deregulation can create an imbalance in tissue homeostasis, with chronic ulceration versus cancer at the extremes of chronic bladder disease Prof. Jenny Southgate, Director, Jack Birch Unit, Department of Biology, University of York, England 3

4 13:10 Lunch Networking Poster presentation One to One Meetings 14:10 Solution Provider Presentation; contact Clinical Epigenetics and Biomarkers 14:40 DNA methylation biomarkers for early and non-invasive detection and monitoring of bladder cancer Using methylome sequencing (RRBS) to identify high performing DNA methylation biomarkers specifi c for bladder cancer Leveraging biomarkers to reducing the mortality and economical costs of bladder cancer Prof. Guro Elisabeth Lind, Group leader Epigenetics, Department of Molecular Oncology, Institute for cancer research, Oslo University hospital, Norway 15:05 Genetics or Lifestyle: Is Epigenetics the Missing link in the Longevity Phenotype? Human longevity is a complex trait and increasingly we recognise that both genes and lifestyle interact in the longevity phenotype. Family clusters of nonagenarian and centenarian siblings, who show both exceptional age-span and health-span are likely to have inherited facilitatory gene groups but also have nine decades of life experiences and behaviours which have interacted with their genetic profi les. Although much remains to be discovered, this lecture will discuss some of the epigenetic and environmental factors which appear important in good quality longevity and link known epigenetic mechanisms to themes identifi ed by nonagenarians themselves related to their longevity. Prof. Irene Maeve Rea, Emeritus Professor School of Medicine, Dentistry and Biomedical Science, Ulster University, Ireland 15:30 Afternoon Refreshments Poster Presentation Networking One to One Meetings 16:15 Solution Provider Presentation; contact steve.h@mnmconferences.com 16:45 DNA methylation markers for management of cancer: pitfalls and perspectives Discovery of DNA methylation markers Implementation of methylation markers into clinical practice Pitfalls and perspectives Prof. Dr. Manon van Engeland, Dept. of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Netherlands 17:10 Decoding the 3D Multi-Loop Aggregate/Rosette Chromatin Architecture, Dynamics, and Functional Epigenetics of Genomes Novel combination of chromosome interaction capture (T2C) and fl uorescence correlation spectroscopy (FCS) Final architecture and dynamics of genome organization The tight entanglement of sequence, structure, and functional epigenetics Dr. Tobias A. Knoch, Group Leader Biophysical Genomics, Cell Biology & Genetics, Erasmus MC, Rotterdam, The Netherlands 17:35 Closing Remarks by the Chair 17:45 Networking and Drinks Reception Supporting Association: THE EPIGENETICS SOCIETY 4

5 Conference Day Two, Friday, 9 th September :15 Registration and Refreshments 08:50 MnM Conferences Welcome Address 08:55 Opening remarks by the Chair 09:00 Keynote: Drug Discovery and HMTs Overview of Histone Methyl transferases Drug discovery of HMTs Clinical Data of HMTs so far Dr. Richard Chesworth, Senior Vice President Research, Epizyme, USA Epigenetics Inhibitors and Emerging Targets 09:25 KATching lysine acetylations in inflammation Role of lysine acetylation in infl ammation Development of histone acetyltransferase inhibitors Selective HDAC inhibitors in infl ammation Prof. Dr. Frank Dekker, Associate professor, Medicinal Chemistry, University of Groningen, Netherlands 09:50 Targeting DNA methylation in cancer cells with non-nucleoside inhibitors We have designed novel non-nucleoside inhibitors of DNA methyltransferases able to demethylate and reactive tumor suppressor genes. We applied three chemical strategies: High-Throughput Screening of chemical libraries, rational drug design based on molecular modeling and the pharmacomodulation of known inhibitors. The cellular consequences of this DNA demethylation are studied in comparison to nucleoside inhibitor decitabine. Dr. Paola B. Arimondo, CNRS, ETaC, France 10:15 Panel discussion Fostering the culture of collaborations between industry and academic researchers to deliver innovation, translation and impact of epigenetics on a global scale Nurturing translational research Initiating drug discovery projects in collaboration with industry Improving clinical development -Dr. Stephen Shuttleworth, CSO, Karus Therapeutics, UK -Prof. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK - Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of harmacology and Therapeutics, McGill University Medical School, Canada -Prof. Jenny Southgate, Director, Jack Birch Unit, Department of Biology, University of York, England 10:45 Morning Refreshments Networking Poster presentation and One to One meetings 11:30 Solution Provider Presentation; Please contact Steve Hambrook at steve.h@mnmconferences.com 12:00 Strategies to identify new inhibitor scaffolds for Histone Demethylases and Methylases Strategies to discover new scaffolds: small molecules and peptides DNA encoded peptide libraries Fluorescence Assay development and testing on epigenetic targets Dr. Brian Lohse, Associate Professor, EpiDiscoverY, Faculty of Health and Medical Sciences, Department of Drug Design and Pharmacology, University of Copenhagen, Denmark 12:25 Is two better than one? Multitarget epigenetic inhibitors Dual HDAC plus kinase inhibitors Dual HDAC inhibitor plus receptor ligand Dual epigenetic targeting Prof. A. Ganesan, Professor of Chemical Biology, University of East Anglia, Norwich, UK 5

6 12:50 Probing genome readers: the generation of an in vivo active bromodomain inhibitor for BRD9 The BAF complex is a potential target in cancer therapy Structure based drug design of a selective inhibitor of BRD9 On-target chemical inhibition of Brd9 limits the proliferation of acute myeloid leukemia cells Dr. Manfred Koegl, Director Oncology Research, Boehringer Ingelheim, Vienna, Austria 13:15 Lunch Networking Poster presentation and One to One Meetings 14:15 Presentation by Diagenode Cancer and Neurodevelopment 14:45 Targeting DNA methylation in neuropsychiatric disease; instructions from cancer epigenetics DNA methylation mediating the impact of early exposures on behavioral phenotypes Strategies of epigenetic therapeutics in cancer guiding approaches to neuropsychiatry Epigenetic strategies towards treatment of behavioral disorders: addiction as a model Dr. Moshe Szyf, Glaxo Smith Kline and James McGill Professor, Department of harmacology and Therapeutics, McGill University Medical School, Canada 15:10 Development of LSD1 inhibitors for the treatment of oncological and neurodegenerative disease Development of ORY-1001 and ORY-2001 Identifi cation of the drugs modes of action Status of ongoing clinical research Dr. Tamara Maes, Chief Scientifi c Offi cer, Oryzon, Spain 15:35 Design and Development of a Novel HDAC6-Selective Inhibitor, KA2507, for Hematological Cancer Treatment and Solid Tumor Immunotherapy Functional mechanisms of lncrnas Application of high-throughput technologies, to clarify how lncrnas regulate diverse biological processes in physiological and pathophysiological states Dr. Stephen Shuttleworth, CSO, Karus Therapeutics, UK 16:00 Afternoon Refreshments Poster Presentation Networking Bioinformatics Development in Epigenetics 16:40 A computational approach for identification of protein-rna interactions uncovers direct binders of Xist lncrna Global Score algorithm to calculate interactions of proteins and lncrnas at nucleotide and amino acid resolution Investigating protein binding to the Xist lncrna, which orchestrates X Chromosome inactivation Validating calculations by means of enhanced individual nucleotide CLIP method (eclip) Testing method against a number of nucleotide-binding proteins Dr. Gian Gaetano Tartaglia, Group Leader, gene Function & Evolution, Centre for Genomic Regulation (CRG), Barcelona, Spain 17:05 Role of bioinformatics in overcoming the challenges of collating epigenetics data together Identifying novel tools and methods to anaylse epigenetics data for experimental validation How can bioinformatics facilitate epigenetics researches? Recent advancements in bioinformatics for epigenetics drug discovery Speaker: TBA 17:30 Closing Remarks by the Chair Media Partner 6

Annual Academic Meeting (Incorporating the Annual Blair Bell Research Society Competition) Joint RCOG/Blair Bell Research Society

Annual Academic Meeting (Incorporating the Annual Blair Bell Research Society Competition) Joint RCOG/Blair Bell Research Society Thursday 17 Friday 18 January 2019 Location: RCOG Overview The Annual Academic